Previous close | 221.79 |
Open | 224.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 224.00 - 230.12 |
52-week range | 154.10 - 230.12 |
Volume | |
Avg. volume | 7,518 |
Market cap | 647.667M |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | 0.59 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The headline numbers for Ecolab (ECL) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Robust Growth and Strategic Divestitures Highlight Ecolab's First Quarter
Water solutions company Ecolab said on Tuesday it would sell its global surgical solutions business to private medical supplier Medline for $950 million in cash and raised its full-year profit forecast. The unit made more than $400 million in sales last year and supplies sterile drape solutions for surgeons, patients and operating room equipment. "This transaction builds on the deliberate actions we've taken to lay the foundation to transform our global healthcare business into a high-quality Ecolab business," said Ecolab CEO Christophe Beck.